Alan Wookey

Three key decisions cell and gene therapy trial sponsors need to make early into drug development

In the rapidly growing and innovative therapeutic area, how do clinical trial sponsors effectively navigate the multitude of unique intricacies involved in cell and gene therapy development? 

In a recent joint thought leadership article for PharmaPhorum, IQVIA experts Patrick Brady and Diego Correa and Q2 Solutions' Alan Wookey discuss several noteworthy considerations that impact complex Cell and Gene Therapy (CAGT) development. This can include the coordination and oversight of end-to-end laboratory assessments and evolving regulatory guidance in a fast-paced landscape. 

These experts' collective insights emphasize the importance of accounting for the wide-ranging spectrum of needs for CAGT development and accordingly mapping out key decisions early in the trial planning process